MREO
Price
$2.37
Change
+$0.20 (+9.22%)
Updated
Apr 2 closing price
Capitalization
376.83M
41 days until earnings call
VKTX
Price
$25.68
Change
+$1.77 (+7.40%)
Updated
Apr 2 closing price
Capitalization
2.88B
20 days until earnings call
Ad is loading...

MREO vs VKTX

Header iconMREO vs VKTX Comparison
Open Charts MREO vs VKTXBanner chart's image
Mereo BioPharma Group
Price$2.37
Change+$0.20 (+9.22%)
Volume$1.57M
Capitalization376.83M
Viking Therapeutics
Price$25.68
Change+$1.77 (+7.40%)
Volume$4.42M
Capitalization2.88B
MREO vs VKTX Comparison Chart
Loading...
MREO
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
VKTX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
MREO vs. VKTX commentary
Apr 03, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is MREO is a Buy and VKTX is a StrongBuy.

Ad is loading...
COMPARISON
Comparison
Apr 03, 2025
Stock price -- (MREO: $2.37 vs. VKTX: $25.68)
Brand notoriety: MREO and VKTX are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: MREO: 129% vs. VKTX: 99%
Market capitalization -- MREO: $376.83M vs. VKTX: $2.88B
MREO [@Biotechnology] is valued at $376.83M. VKTX’s [@Biotechnology] market capitalization is $2.88B. The market cap for tickers in the [@Biotechnology] industry ranges from $308.32B to $0. The average market capitalization across the [@Biotechnology] industry is $2.19B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

MREO’s FA Score shows that 1 FA rating(s) are green whileVKTX’s FA Score has 0 green FA rating(s).

  • MREO’s FA Score: 1 green, 4 red.
  • VKTX’s FA Score: 0 green, 5 red.
According to our system of comparison, both MREO and VKTX are a bad buy in the long-term.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

MREO’s TA Score shows that 4 TA indicator(s) are bullish while VKTX’s TA Score has 4 bullish TA indicator(s).

  • MREO’s TA Score: 4 bullish, 4 bearish.
  • VKTX’s TA Score: 4 bullish, 3 bearish.
According to our system of comparison, VKTX is a better buy in the short-term than MREO.

Price Growth

MREO (@Biotechnology) experienced а 0.00% price change this week, while VKTX (@Biotechnology) price change was -2.51% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -5.26%. For the same industry, the average monthly price growth was -7.43%, and the average quarterly price growth was -11.99%.

Reported Earning Dates

MREO is expected to report earnings on May 14, 2025.

VKTX is expected to report earnings on Apr 23, 2025.

Industries' Descriptions

@Biotechnology (-5.26% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
VKTX($2.88B) has a higher market cap than MREO($377M). MREO YTD gains are higher at: -32.286 vs. VKTX (-36.183). MREO has higher annual earnings (EBITDA): -43.41M vs. VKTX (-150.58M). VKTX has more cash in the bank: 903M vs. MREO (80.5M). VKTX has less debt than MREO: VKTX (1.12M) vs MREO (6.68M). MREO has higher revenues than VKTX: MREO (1M) vs VKTX (0).
MREOVKTXMREO / VKTX
Capitalization377M2.88B13%
EBITDA-43.41M-150.58M29%
Gain YTD-32.286-36.18389%
P/E RatioN/AN/A-
Revenue1M0-
Total Cash80.5M903M9%
Total Debt6.68M1.12M597%
FUNDAMENTALS RATINGS
MREO vs VKTX: Fundamental Ratings
MREO
VKTX
OUTLOOK RATING
1..100
1176
VALUATION
overvalued / fair valued / undervalued
1..100
77
Overvalued
45
Fair valued
PROFIT vs RISK RATING
1..100
9071
SMR RATING
1..100
9893
PRICE GROWTH RATING
1..100
8793
P/E GROWTH RATING
1..100
2100
SEASONALITY SCORE
1..100
n/a22

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

VKTX's Valuation (45) in the Biotechnology industry is in the same range as MREO (77) in the null industry. This means that VKTX’s stock grew similarly to MREO’s over the last 12 months.

VKTX's Profit vs Risk Rating (71) in the Biotechnology industry is in the same range as MREO (90) in the null industry. This means that VKTX’s stock grew similarly to MREO’s over the last 12 months.

VKTX's SMR Rating (93) in the Biotechnology industry is in the same range as MREO (98) in the null industry. This means that VKTX’s stock grew similarly to MREO’s over the last 12 months.

MREO's Price Growth Rating (87) in the null industry is in the same range as VKTX (93) in the Biotechnology industry. This means that MREO’s stock grew similarly to VKTX’s over the last 12 months.

MREO's P/E Growth Rating (2) in the null industry is significantly better than the same rating for VKTX (100) in the Biotechnology industry. This means that MREO’s stock grew significantly faster than VKTX’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
MREOVKTX
RSI
ODDS (%)
Bullish Trend 2 days ago
89%
Bullish Trend 1 day ago
78%
Stochastic
ODDS (%)
Bullish Trend 2 days ago
80%
Bullish Trend 1 day ago
82%
Momentum
ODDS (%)
Bearish Trend 2 days ago
84%
Bearish Trend 1 day ago
84%
MACD
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 1 day ago
85%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
88%
Bearish Trend 1 day ago
86%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
87%
Bearish Trend 1 day ago
87%
Advances
ODDS (%)
Bullish Trend 7 days ago
81%
Bullish Trend 10 days ago
82%
Declines
ODDS (%)
Bearish Trend 2 days ago
87%
Bearish Trend 2 days ago
85%
BollingerBands
ODDS (%)
Bullish Trend 2 days ago
90%
Bullish Trend 1 day ago
90%
Aroon
ODDS (%)
Bearish Trend 2 days ago
87%
N/A
View a ticker or compare two or three
Ad is loading...
MREO
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
VKTX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
AIONX15.790.07
+0.45%
AQR International Momentum Style N
SMBYX37.78N/A
N/A
ClearBridge Mid Cap I
SIFAX8.14N/A
N/A
SEI Multi-Asset Inflation Mgd F (SIMT)
TREPX14.09N/A
N/A
Nuveen International Eq Premier
EFCNX18.50N/A
N/A
Emerald Insights Investor